Product Description
Retatrutide's efficacy lies in its triple receptor activation:
● GLP-1 Agonist: Enhances glucose-dependent insulin secretion, promotes satiety, and slows gastric emptying.
● GIP Agonist: Regulates appetite control and insulin sensitivity, promoting overall metabolic balance.
● Glucagon Receptor Activation: Increases energy expenditure and fat oxidation, contributing to weight loss.
This integrated approach to metabolic regulation makes Retatrutide a promising candidate for treating obesity, metabolic syndrome, and type-2 diabetes with more comprehensive therapeutic effects compared to traditional single-target peptides.
Retatrutide has shown substantial weight loss in clinical trials, making it a highly sought-after peptide for obesity management. Its dual effect on glucose metabolism and appetite suppression helps patients experience significant body fat reduction, improving both health outcomes and quality of life.
As a dual-action peptide, Retatrutide enhances insulin secretion and glucose regulation, leading to more consistent and effective blood sugar management for patients with type-2 diabetes.
With its extended half-life, Retatrutide can be administered as a weekly injection, offering patients greater convenience compared to daily medications. This longer duration of action enhances patient compliance and reduces the need for frequent injections, improving the overall treatment experience.
Retatrutide is synthesized under stringent quality controls, ensuring:
● ≥98% purity (by HPLC)
● Stable under recommended storage conditions
● Free from contaminants such as endotoxins and microbial growth
|
Parameter |
Description |
|
CAS Number |
2381089-83-2 |
|
Molecular Formula |
C174H272N50O57S2 |
|
Molecular Weight |
4057.87 g/mol |
|
Sequence |
Not disclosed in full due to intellectual property protections. |
|
Appearance |
Lyophilized powder, white to off-white solid |
|
Storage Conditions |
Store at -20°C, protected from light |
|
Specification |
Option |
|
Purity |
≥98% (HPLC) |
|
Form |
Lyophilized powder |
|
Vial Sizes |
1mg, 5mg, 10mg, 50mg vials (bulk or custom packaging options) |
|
Packaging |
Individually sealed, sterile packaging with moisture and temperature controls |
|
Shelf Life |
24 months from manufacture (when stored at recommended conditions) |
Retatrutide's mechanism of action makes it an ideal peptide for various metabolic disease research applications, including:
● Obesity Research: Understanding the pathways of satiety, fat oxidation, and glucose homeostasis.
● Type-2 Diabetes Management: Investigating the dual impact on insulin secretion and glucose control.
● Endocrine Regulation: Exploring its combined receptor actions for future therapeutic innovations in diabetes, metabolic disorders, and obesity treatments.
● Pharmacokinetic Studies: Examining its long half-life and sustained release profile to improve delivery systems in preclinical models.
Retatrutide holds great potential for clinical trials and pharmaceutical development, contributing to drug discovery, early-stage therapeutic formulations, and the optimization of peptide-based treatments.
